Highlights
KLSE: AHEALTH (7090)       APEX HEALTHCARE BHD MAIN : Health Care
Last Price Today's Change   Day's Range   Trading Volume
2.92   0.00 (0.00%)  2.91 - 2.92  9,000
Trade this stock for as low as 0.05% brokerage. Find out more.

Financials


Market Cap: 1,390 Million

Market Cap 1,390 Million
NOSH 476 Million

Latest Audited Result:  31-Dec-2020

Latest Audited Result: 31-Dec-2020
Announcement Date 21-Apr-2021
Next Audited Result: 31-Dec-2021
Est. Ann. Date: 21-Apr-2022
Est. Ann. Due Date: 29-Jun-2022

Latest Quarter:  31-Mar-2021 [#1]

Latest Quarter: 31-Mar-2021 [#1]
Announcement Date 20-May-2021
Next Quarter: 30-Jun-2021
Est. Ann. Date: 26-Aug-2021
Est. Ann. Due Date: 29-Aug-2021
QoQ | YoY   -17.47%  |    -17.33%

Annual (Unaudited) ( EPS: 11.77, P/E: 24.80 )

Revenue | NP to SH 698,729  |  56,021
RPS | P/RPS 146.83 Cent  |  1.99
EPS | P/E | EY 11.77 Cent  |  24.80  |  4.03%
DPS | DY | Payout % 4.47 Cent  |  1.53%  |  38.00%
NAPS | P/NAPS 0.98  |  2.97
YoY   6.20%
NP Margin | ROE 8.02%  |  11.96%
F.Y. | Ann. Date 31-Dec-2020  |  25-Feb-2021

T4Q Result ( EPS: 11.25, P/E: 25.96 )

Revenue | NP to SH 684,907  |  53,530
RPS | P/RPS 143.92 Cent  |  2.03
EPS | P/E | EY 11.25 Cent  |  25.96  |  3.85%
DPS | DY | Payout % 4.47 Cent  |  1.53%  |  39.75%
NAPS | P/NAPS 1.00  |  2.91
QoQ | YoY   -4.45%  |    -3.93%
NP Margin | ROE 7.81%  |  11.20%
F.Y. | Ann. Date 31-Mar-2021  |  20-May-2021

Annualized Result ( EPS: 9.98, P/E: 29.24 )

Revenue | NP to SH 717,944  |  47,516
RPS | P/RPS 150.87 Cent  |  1.94
EPS | P/E | EY 9.98 Cent  |  29.24  |  3.42%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   -15.18%  |    -17.33%
NP Margin | ROE 6.62%  |  9.94%
F.Y. | Ann. Date 31-Mar-2021  |  20-May-2021


Hints :
Click the QoQ or YoY on table to view the QoQ or YoY Financial Result page.

Click here to modify the Visible Columns.

Date Financial Result Financial Ratio Per Share Item Performance Valuation (End of Quarter) Valuation (Ann. Date)
F.Y. Ann. Date Quarter # Revenue PBT NP NP to SH Div Net Worth Div Payout % NP Margin ROE NOSH RPS Adj. RPS EPS Adj. EPS DPS Adj. DPS NAPS Adj. NAPS QoQ YoY EOQ Date EOQ Price EOQ P/RPS EOQ P/EPS EOQ P/NAPS EOQ EY EOQ DY ANN Date ANN Price ANN P/RPS ANN P/EPS ANN P/NAPS ANN EY ANN DY
31-Dec-2021 20-May-2021 31-Mar-2021 1 179,486 15,436 11,876 11,879 - 477,968 - % 6.62% 2.49% 473,236 37.93 37.72 2.51 2.50 0.00 0.00 1.0100 1.00   -17.47%   -17.33% 31-Mar-2021 2.93 7.73 116.73 2.90 0.86% 0.00% 2.90 7.65 115.53 2.87 0.87% 0.00%
31-Dec-2020 25-Feb-2021 31-Dec-2020 4 161,577 18,401 14,373 14,394 13,245 468,317 92.02% 8.90% 3.07% 473,048 34.16 33.95 3.04 3.02 2.80 2.78 0.9900 0.98   1.20%   2.78% 31-Dec-2020 3.54 10.36 116.34 3.58 0.86% 0.79% 25-Feb-2021 3.30 9.66 108.45 3.33 0.92% 0.85%
31-Dec-2020 19-Nov-2020 30-Sep-2020 3 169,116 17,488 14,346 14,223 - 454,102 - % 8.48% 3.13% 473,023 35.75 35.54 3.01 2.99 0.00 0.00 0.9600 0.95   9.12%   0.71% 30-Sep-2020 3.24 9.06 107.75 3.38 0.93% 0.00% 19-Nov-2020 3.60 10.07 119.73 3.75 0.84% 0.00%
31-Dec-2020 26-Aug-2020 30-Jun-2020 2 174,728 16,341 12,930 13,034 8,032 444,145 61.63% 7.40% 2.93% 472,495 36.98 36.72 2.76 2.74 1.70 1.69 0.9400 0.93   -9.30%   -1.44% 30-Jun-2020 2.80 7.57 101.50 2.98 0.99% 0.61% 26-Aug-2020 3.72 10.06 134.85 3.96 0.74% 0.46%
31-Dec-2020 21-May-2020 31-Mar-2020 1 193,308 17,944 14,362 14,370 - 438,661 - % 7.43% 3.28% 471,679 40.98 40.62 3.05 3.02 0.00 0.00 0.9300 0.92   2.61%   26.06% 31-Mar-2020 2.11 5.15 69.26 2.27 1.44% 0.00% 21-May-2020 2.90 7.08 95.19 3.12 1.05% 0.00%
31-Dec-2019 19-Feb-2020 31-Dec-2019 4 170,634 18,484 14,006 14,004 9,426 424,170 67.31% 8.21% 3.30% 471,301 36.20 35.86 2.97 2.94 2.00 1.98 0.9000 0.89   -0.84%   -16.66% 31-Dec-2019 2.24 6.19 75.39 2.49 1.33% 0.89% 19-Feb-2020 2.41 6.66 81.11 2.68 1.23% 0.83%
31-Dec-2019 21-Nov-2019 30-Sep-2019 3 180,653 17,124 14,122 14,123 - 409,992 - % 7.82% 3.44% 471,256 38.33 37.96 3.00 2.97 0.00 0.00 0.8700 0.86   6.80%   -5.20% 30-Sep-2019 2.18 5.69 72.74 2.51 1.37% 0.00% 21-Nov-2019 2.40 6.26 80.08 2.76 1.25% 0.00%
31-Dec-2019 21-Aug-2019 30-Jun-2019 2 159,270 16,183 13,230 13,224 8,008 405,125 60.56% 8.31% 3.26% 471,076 33.81 33.47 2.81 2.78 1.70 1.68 0.8600 0.85   16.01%   -3.47% 28-Jun-2019 2.17 6.42 77.30 2.52 1.29% 0.78% 21-Aug-2019 2.03 6.00 72.31 2.36 1.38% 0.84%
31-Dec-2019 23-May-2019 31-Mar-2019 1 178,229 14,543 11,414 11,399 - 392,099 - % 6.40% 2.91% 117,395 151.82 37.45 9.71 2.40 0.00 0.00 3.3400 0.82   -32.16%   -13.52% 29-Mar-2019 8.87 5.84 91.35 2.66 1.09% 0.00% 23-May-2019 8.60 5.66 88.57 2.57 1.13% 0.00%
31-Dec-2018 28-Feb-2019 31-Dec-2018 4 163,061 16,739 16,803 16,804 8,210 381,202 48.86% 10.30% 4.41% 117,293 139.02 34.26 14.33 3.53 7.00 1.73 3.2500 0.80   12.80%   31.27% 31-Dec-2018 7.80 5.61 54.44 2.40 1.84% 0.90% 28-Feb-2019 8.95 6.44 62.47 2.75 1.60% 0.78%
31-Dec-2018 15-Nov-2018 30-Sep-2018 3 165,253 18,637 14,942 14,897 - 365,595 - % 9.04% 4.07% 117,178 141.03 34.73 12.71 3.13 0.00 0.00 3.1200 0.77   8.75%   32.18% 28-Sep-2018 8.25 5.85 64.89 2.64 1.54% 0.00% 15-Nov-2018 8.10 5.74 63.71 2.60 1.57% 0.00%
31-Dec-2018 16-Aug-2018 30-Jun-2018 2 155,946 17,368 13,701 13,699 7,614 360,809 55.58% 8.79% 3.80% 117,146 133.12 32.77 11.69 2.88 6.50 1.60 3.0800 0.76   3.93%   33.04% 29-Jun-2018 6.79 5.10 58.06 2.20 1.72% 0.96% 16-Aug-2018 7.25 5.45 62.00 2.35 1.61% 0.90%
31-Dec-2018 24-May-2018 31-Mar-2018 1 168,400 16,526 13,221 13,181 - 356,123 - % 7.85% 3.70% 117,146 143.75 35.39 11.25 2.77 0.00 0.00 3.0400 0.75   2.97%   30.62% 30-Mar-2018 5.48 3.81 48.70 1.80 2.05% 0.00% 24-May-2018 5.76 4.01 51.19 1.89 1.95% 0.00%
31-Dec-2017 22-Feb-2018 31-Dec-2017 4 152,585 16,380 12,799 12,801 7,614 343,237 59.48% 8.39% 3.73% 117,146 130.25 32.06 10.93 2.69 6.50 1.60 2.9300 0.72   13.58%   89.48% 29-Dec-2017 5.60 4.30 51.25 1.91 1.95% 1.16% 22-Feb-2018 4.90 3.76 44.84 1.67 2.23% 1.33%
31-Dec-2017 14-Nov-2017 30-Sep-2017 3 157,730 13,302 11,290 11,270 - 330,351 - % 7.16% 3.41% 117,146 134.64 33.14 9.62 2.37 0.00 0.00 2.8200 0.69   9.45%   29.01% 29-Sep-2017 5.10 3.79 53.01 1.81 1.89% 0.00% 14-Nov-2017 5.50 4.08 57.17 1.95 1.75% 0.00%
31-Dec-2017 16-Aug-2017 30-Jun-2017 2 155,297 13,453 10,300 10,297 6,443 325,665 62.57% 6.63% 3.16% 117,146 132.57 32.63 8.79 2.16 5.50 1.35 2.7800 0.68   2.04%   6.72% 30-Jun-2017 4.70 3.55 53.47 1.69 1.87% 1.17% 16-Aug-2017 4.74 3.58 53.93 1.71 1.85% 1.16%
31-Dec-2017 17-May-2017 31-Mar-2017 1 154,652 12,912 10,099 10,091 - 322,151 - % 6.53% 3.13% 117,146 132.02 32.50 8.61 2.12 0.00 0.00 2.7500 0.68   49.36%   2.83% 31-Mar-2017 4.90 3.71 56.88 1.78 1.76% 0.00% 17-May-2017 4.70 3.56 54.56 1.71 1.83% 0.00%
31-Dec-2016 23-Feb-2017 31-Dec-2016 4 144,146 10,079 6,766 6,756 7,028 311,608 104.04% 4.69% 2.17% 117,146 123.05 30.29 5.77 1.42 6.00 1.48 2.6600 0.65   -22.66%   -51.06% 30-Dec-2016 4.30 3.49 74.56 1.62 1.34% 1.40% 23-Feb-2017 4.65 3.78 80.63 1.75 1.24% 1.29%
31-Dec-2016 15-Nov-2016 30-Sep-2016 3 142,960 11,536 8,748 8,736 - 301,065 - % 6.12% 2.90% 117,146 122.04 30.04 7.46 1.84 0.00 0.00 2.5700 0.63   -9.46%   62.35% 30-Sep-2016 4.54 3.72 60.88 1.77 1.64% 0.00% 15-Nov-2016 4.60 3.77 61.68 1.79 1.62% 0.00%
31-Dec-2016 17-Aug-2016 30-Jun-2016 2 146,685 12,313 9,655 9,649 6,443 298,722 66.77% 6.58% 3.23% 117,146 125.22 30.82 8.24 2.03 5.50 1.35 2.5500 0.63   -1.67%   46.13% 30-Jun-2016 3.89 3.11 47.23 1.53 2.12% 1.41% 17-Aug-2016 3.82 3.05 46.38 1.50 2.16% 1.44%
31-Dec-2016 18-May-2016 31-Mar-2016 1 147,478 12,366 9,819 9,813 - 296,379 - % 6.66% 3.31% 117,146 125.89 30.99 8.38 2.06 0.00 0.00 2.5300 0.62   -28.92%   16.19% 31-Mar-2016 3.73 2.96 44.53 1.47 2.25% 0.00% 18-May-2016 3.94 3.13 47.04 1.56 2.13% 0.00%
31-Dec-2015 25-Feb-2016 31-Dec-2015 4 134,248 17,165 13,827 13,806 7,028 288,179 50.91% 10.30% 4.79% 117,146 114.60 28.21 11.79 2.90 6.00 1.48 2.4600 0.61   156.57%   44.64% 31-Dec-2015 3.60 3.14 30.55 1.46 3.27% 1.67% 25-Feb-2016 3.41 2.98 28.93 1.39 3.46% 1.76%
31-Dec-2015 26-Nov-2015 30-Sep-2015 3 128,268 7,721 5,388 5,381 - 274,121 - % 4.20% 1.96% 117,146 109.49 26.95 4.59 1.13 0.00 0.00 2.3400 0.58   -18.51%   -27.38% 30-Sep-2015 3.95 3.61 85.99 1.69 1.16% 0.00% 26-Nov-2015 3.70 3.38 80.55 1.58 1.24% 0.00%
31-Dec-2015 19-Aug-2015 30-Jun-2015 2 124,279 9,076 6,602 6,603 5,857 268,264 88.71% 5.31% 2.46% 117,146 106.09 26.12 5.64 1.39 5.00 1.23 2.2900 0.56   -21.82%   -12.59% 30-Jun-2015 4.02 3.79 71.32 1.76 1.40% 1.24% 19-Aug-2015 3.95 3.72 70.08 1.72 1.43% 1.27%
31-Dec-2015 20-May-2015 31-Mar-2015 1 140,064 11,880 8,446 8,446 - 268,264 - % 6.03% 3.15% 117,146 119.56 29.43 7.21 1.77 0.00 0.00 2.2900 0.56   -11.51%   -10.79% 31-Mar-2015 3.90 3.26 54.09 1.70 1.85% 0.00% 20-May-2015 3.95 3.30 54.79 1.72 1.83% 0.00%
31-Dec-2014 25-Feb-2015 31-Dec-2014 4 123,305 12,671 9,545 9,545 7,028 260,064 73.64% 7.74% 3.67% 117,146 105.26 25.91 8.13 2.01 6.00 1.48 2.2200 0.55   28.81%   24.89% 31-Dec-2014 3.58 3.40 43.94 1.61 2.28% 1.68% 25-Feb-2015 3.64 3.46 44.67 1.64 2.24% 1.65%
31-Dec-2014 18-Nov-2014 30-Sep-2014 3 122,512 10,281 7,410 7,410 - 249,520 - % 6.05% 2.97% 117,146 104.58 25.74 6.30 1.56 0.00 0.00 2.1300 0.52   -1.91%   14.37% 30-Sep-2014 3.86 3.69 61.02 1.81 1.64% 0.00% 18-Nov-2014 3.70 3.54 58.49 1.74 1.71% 0.00%
31-Dec-2014 20-Aug-2014 30-Jun-2014 2 122,493 10,050 7,554 7,554 4,100 246,006 54.28% 6.17% 3.07% 117,146 104.56 25.74 6.42 1.59 3.50 0.86 2.1000 0.52   -20.22%   10.89% 30-Jun-2014 3.80 3.63 58.93 1.81 1.70% 0.92% 20-Aug-2014 3.85 3.68 59.71 1.83 1.67% 0.91%
31-Dec-2014 21-May-2014 31-Mar-2014 1 130,927 12,622 9,468 9,468 - 244,601 - % 7.23% 3.87% 93,717 139.70 27.51 10.07 1.99 0.00 0.00 2.6100 0.51   23.88%   3.90% 31-Mar-2014 4.60 3.29 45.53 1.76 2.20% 0.00% 21-May-2014 4.80 3.44 47.51 1.84 2.10% 0.00%
31-Dec-2013 26-Feb-2014 31-Dec-2013 4 106,210 10,566 7,643 7,643 5,621 235,161 73.55% 7.20% 3.25% 93,690 113.36 22.32 6.50 1.61 6.00 1.18 2.5100 0.49   17.97%   -3.13% 31-Dec-2013 4.50 3.97 55.16 1.79 1.81% 1.33% 26-Feb-2014 4.40 3.88 53.94 1.75 1.85% 1.36%
31-Dec-2013 20-Nov-2013 30-Sep-2013 3 101,680 8,579 6,512 6,479 - 225,030 - % 6.40% 2.88% 93,762 108.44 21.37 6.91 1.36 0.00 0.00 2.4000 0.47   -4.89%   0.61% 30-Sep-2013 4.80 4.43 69.46 2.00 1.44% 0.00% 20-Nov-2013 4.79 4.42 69.32 2.00 1.44% 0.00%
31-Dec-2013 21-Aug-2013 30-Jun-2013 2 104,202 9,273 6,833 6,812 3,748 223,006 55.02% 6.56% 3.05% 93,700 111.21 21.90 7.27 1.43 4.00 0.79 2.3800 0.47   -25.25%   -18.54% 28-Jun-2013 4.49 4.04 61.76 1.89 1.62% 0.89% 21-Aug-2013 4.95 4.45 68.09 2.08 1.47% 0.81%
31-Dec-2013 22-May-2013 31-Mar-2013 1 106,359 12,197 9,134 9,113 - 225,949 - % 8.59% 4.03% 93,755 113.44 22.35 9.72 1.91 0.00 0.00 2.4100 0.47   15.50%   44.19% 29-Mar-2013 4.27 3.76 43.93 1.77 2.28% 0.00% 22-May-2013 4.37 3.85 44.96 1.81 2.22% 0.00%
31-Dec-2012 27-Feb-2013 31-Dec-2012 4 95,993 9,918 7,898 7,890 10,312 216,569 130.71% 8.23% 3.64% 93,752 102.39 20.17 8.42 1.66 11.00 2.17 2.3100 0.46   22.52%   -1.38% 31-Dec-2012 3.68 3.59 43.73 1.59 2.29% 2.99% 27-Feb-2013 4.14 4.04 49.19 1.79 2.03% 2.66%
31-Dec-2012 21-Nov-2012 30-Sep-2012 3 97,807 8,771 6,457 6,440 - 208,104 - % 6.60% 3.09% 93,740 104.34 20.55 6.87 1.35 0.00 0.00 2.2200 0.44   -22.98%   39.79% 28-Sep-2012 3.28 3.14 47.74 1.48 2.09% 0.00% 21-Nov-2012 3.56 3.41 51.82 1.60 1.93% 0.00%
31-Dec-2012 15-Aug-2012 30-Jun-2012 2 100,678 11,333 8,374 8,362 5,624 206,237 67.26% 8.32% 4.05% 93,744 107.40 21.16 8.92 1.76 6.00 1.18 2.2000 0.43   32.31%   28.19% 29-Jun-2012 2.95 2.75 33.07 1.34 3.02% 2.03% 15-Aug-2012 3.11 2.90 34.87 1.41 2.87% 1.93%
31-Dec-2012 23-May-2012 31-Mar-2012 1 104,126 12,327 6,337 6,320 - 205,353 - % 6.09% 3.08% 93,768 111.05 21.88 6.74 1.33 0.00 0.00 2.1900 0.43   -21.00%   -28.78% 30-Mar-2012 2.94 2.65 43.62 1.34 2.29% 0.00% 23-May-2012 2.78 2.50 41.25 1.27 2.42% 0.00%
31-Dec-2011 23-Feb-2012 31-Dec-2011 4 92,330 9,314 7,992 8,000 9,376 198,784 117.21% 8.66% 4.02% 93,766 98.47 19.40 8.54 1.68 10.00 1.97 2.1200 0.42   73.65%   -39.46% 30-Dec-2011 2.74 2.78 32.11 1.29 3.11% 3.65% 23-Feb-2012 2.83 2.87 33.17 1.33 3.01% 3.53%
31-Dec-2011 15-Nov-2011 30-Sep-2011 3 91,867 6,125 4,623 4,607 - 190,085 - % 5.03% 2.42% 93,638 98.11 19.30 4.92 0.97 0.00 0.00 2.0300 0.40   -29.37%   -36.21% 30-Sep-2011 2.60 2.65 52.85 1.28 1.89% 0.00% 15-Nov-2011 2.84 2.89 57.72 1.40 1.73% 0.00%
31-Dec-2011 19-Aug-2011 30-Jun-2011 2 88,983 8,738 6,666 6,523 5,153 189,284 79.01% 7.49% 3.45% 93,705 94.96 18.70 6.96 1.37 5.50 1.08 2.0200 0.40   -26.49%   12.47% 30-Jun-2011 3.05 3.21 43.81 1.51 2.28% 1.80% 19-Aug-2011 2.92 3.07 41.95 1.45 2.38% 1.88%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.


NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.


Analyze this stock with MQ Trader system
  4 people like this.
 
Mr.Sm Invest123 Tomorrow Fly over 4.50
20/11/2020 12:10 AM
Mr.Sm Invest123 Accumulating more
20/11/2020 12:20 AM
Sinoboy Looking good. Steady she goes, don't falter
20/11/2020 11:52 AM
chshzhd keep..
20/11/2020 4:59 PM
JaBerry Yes keep
23/11/2020 9:22 AM
NPRA1985 Post removed. Why?
23/11/2020 2:00 PM
JaBerry Waiting for vaccines come another distribution income.
27/11/2020 9:36 AM
mrmeow AHEALTH has the cold storage facility and has expanded by acquiring more cold facility and prepared for the covid19 vaccines. Don't foget this real making money one, supplying Msia and Singapore, stable & growing business even before covid, always on an uptrend
27/11/2020 9:41 AM
mrmeow Everyone looking for logistics company that has cold facility for vaccine distribution, yet they forget that this pharmaceutical company does distribution too and has the logistics capable of doing the real work
27/11/2020 12:00 PM
Mr.Sm Invest123 Vaccine-related: Following the approval of Budget 2021, vaccine-related companies will benefit under the Covid-19 fund/fill-and-finish process as well as distribution of vaccines once it is available in the future. Under this segment, SOLUTN, HWGB, BINTAI, DPHARMA, PHARMA, KANGER, -Ahealth, TITIJYA, MAHSING should be under traders radar.

Source: M+ Online
27/11/2020 12:47 PM
serendipity89 ''Apex has been approached by several manufacturers to be the authorised distributor for their upcoming Covid-19 vaccines (work-in-progress). There are many considerations in evaluating these proposals (ie. whether the products will be approved, pricings, efficiencies, requirements, etc) and hence, Apex has not committed to any manufacturer. Instead, the group will likely start off as a wholesaler, where Apex will distribute the Covid-19 vaccines from various manufacturers''

AffinHWang
28/11/2020 1:30 PM
NPRA1985 PM: No call to reject 2021 Budget just to bring about polls

"There is no need to do that (reject the 2021 Budget). If you ask me, I could have yesterday advised the Yang di-Pertuan Agong Al-Sultan Abdullah Ri'ayatuddin Al-Mustafa Billah Shah, to dissolve Parliament so that a general election can be held.

"But we all know that the problem is Covid-19. InsyaAllah, if He allows it, when the pandemic is over, we can hold a general election.

Muhyiddin added that the 2021 Budget, worth RM322.5 billion which was passed at the policy level in Parliament on Thursday, is aimed at easing the burden of the people and restoring the country's economy.

"I hope the 2021 Budget will be approved at the Dewan Rakyat and subsequently at the Dewan Negara. This is to ensure that the people will receive the assistance that they need during this tough time."

https://www.nst.com.my/news/politics/2020/11/645117/pm-no-call-reject-2021-budget-just-bring-about-polls
29/11/2020 9:25 PM
NPRA1985 No significant change to reject budget at committee level: Dr M

FORMER Prime Minister (PM) Tun Dr Mahathir Mohamad said no significant change can be achieved if the proposed Budget 2021 is rejected at the committee level debate session.

“Rejecting the budget at the committee level, as it is said to be done, will not bring any significant impact on the government nor the proposed budget.

“It is just an attempt to divert the criticisms of the people who are disappointed with the attitude of the Opposition,” Dr Mahathir said in a statement today.

https://themalaysianreserve.com/2020/11/27/no-significant-change-to-reject-budget-at-committee-level-dr-m/
29/11/2020 9:36 PM
weijuin1992 Buy on rumours sell on fact ,it had come so far with rumours ,once confirm news will fly ,sit in if you believe in good company !
01/12/2020 12:08 PM
weijuin1992 Reversal to uptrend on small fraction of price yet big indicator to this share as it is not so volatile like the others , good chance striking up again !
01/12/2020 5:39 PM
NPRA1985 U.K. Approves Pfizer Coronavirus Vaccine, a First in the West
The emergency approval, ahead of the United States and the European Union, clears the way for Britain to begin mass inoculations. “Help is on its way,” one official said.

https://www.nytimes.com/2020/12/02/world/europe/pfizer-coronavirus-vaccine-approved-uk.html
02/12/2020 6:36 PM
NPRA1985 Moderna Covid vaccine can get emergency authorisation approval in 2-3 days after panel meet: CEO

Moderna's vaccine candidate's full results from a late-stage study showed its vaccine was 94.1% effective with no serious safety concerns

https://www.livemint.com/news/world/moderna-covid-vaccine-can-get-emergency-authorisation-approval-in-2-3-days-after-panel-meet-ceo-11606922963960.html
03/12/2020 12:36 AM
NPRA1985 US says Covid-19 vaccines ready to be shipped nationwide immediately

https://www.freemalaysiatoday.com/category/world/2020/12/02/us-says-covid-19-vaccines-ready-to-be-shipped-nationwide-immediately/
03/12/2020 12:37 AM
NPRA1985 Janssen seeks Health Canada approval for its COVID-19 vaccine

https://www.cbc.ca/news/politics/johnson-johnson-health-canada-approval-1.5823173
03/12/2020 12:37 AM
NPRA1985 Johnson & Johnson has started a rolling submission with the European Medicines Agency (EMA) for its single-dose COVID-19 vaccine candidate.

https://www.biopharma-reporter.com/Article/2020/12/01/Johnson-Johnson-start-rolling-review-for-COVID-19-vaccine-in-Europe
03/12/2020 12:38 AM
NPRA1985 Promise of Covid vaccines is ‘phenomenal’, WHO says

https://www.freemalaysiatoday.com/category/world/2020/12/03/promise-of-covid-vaccines-is-phenomenal-who-says/
03/12/2020 10:25 PM
NPRA1985 Equities up as Covid-19 cases drop, vaccine news spurs economic recovery bets

https://www.theedgemarkets.com/article/fbm-klci-closes-2954-points-162826
03/12/2020 10:47 PM
NPRA1985 DUBAI: Bahrain said on Friday it has granted emergency use authorization for the Pfizer/BioNTech COVID-19 vaccine, becoming the second country after Britain to approve it.

The kingdom had also approved Sinopharm’s COVID-19 vaccine in November for use by frontline workers.

https://www.arabnews.com/node/1772516/middle-east
05/12/2020 1:33 AM
NPRA1985 South Korea reaches deal to buy AstraZeneca's Covid-19 vaccine candidate

https://www.straitstimes.com/asia/east-asia/south-korea-reaches-deal-to-buy-astrazenecas-covid-19-vaccine-candidate
05/12/2020 1:46 AM
NPRA1985 500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/
05/12/2020 2:34 PM
NPRA1985 UAE says Sinopharm vaccine has 86% efficacy against COVID-19

DUBAI (Reuters) - An experimental coronavirus vaccine developed by China’s Sinopharm has 86% efficacy against the virus, the United Arab Emirates health ministry said on Wednesday, citing an interim analysis of a human trial underway there.

The Gulf Arab state in July started Phase 3 clinical trials of the vaccine, developed by Beijing Institute of Biological Product, a unit of Sinopharm’s China National Biotec Group (CNBG). In September, the UAE approved its emergency use for certain groups.

The analysis also shows “99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease”, the ministry said in a statement carried by the state news agency.

“The analysis shows no serious safety concerns,” it said.

It also said it had officially registered the vaccine, without elaborating, and that 31,000 volunteers across 125 nationalities participated in the UAE trial.

https://www.reuters.com/article/health-coronavirus-emirates/update-1-uae-says-sinopharm-vaccine-has-86-efficacy-against-covid-19-idUSL1N2IP09V
09/12/2020 3:12 PM
NPRA1985 United Arab Emirates Claims China’s Sinopharm Vaccine Is 100% Effective At Preventing Moderate And Severe Covid-19

TOPLINE The experimental vaccine developed by China National Pharmaceutical Group, also known as Sinopharm, is 86% effective at preventing Covid-19 infection and 100% effective at preventing severe and moderate disease, health officials from the United Arab Emirates announced Wednesday, although with scarce detail provided about the trial.

The UAE health ministry cited an interim analysis of a late-stage clinical trial involving 31,000 volunteers as the source of its information, though neither they nor Sinopharm provided any data from the trial to validate the claims such as how many participants were infected or how many actually received the vaccine.

The ministry said “no serious safety concerns” were observed, though, again, no information on side effects was provided.

The ministry said the announcement is a “significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.”

The ministry added that it had officially registered the vaccine at the request of the manufacturer, which it says could eventually lead to the shot’s widespread authorization.

https://www.forbes.com/sites/roberthart/2020/12/09/united-arab-emirates-claims-chinas-sinopharm-vaccine-is-100-effective-at-preventing-moderate-and-severe-covid-19/?sh=2a60fb42595c
09/12/2020 10:25 PM
NPRA1985 Hong Kong’s Ming Pao daily said in its editorial that there were grounds to believe that the UAE must have been stringent with the review and registration of the Chinese vaccine, given the country’s record of being transparent in its anti-virus policymaking and mass testing.

“The UAE also maintains sound ties with the West so sourcing vaccines from the United States or elsewhere should not be a grave challenge. If the Chinese vaccine is not safe or effective, there is no reason for the UAE to endorse Beijing’s vaccine propaganda and risk its own image and the health of its own people.

“Thus the UAE’s approval and its top leader’s injection of the SinoPharm vaccine have come as a much-needed vote of confidence that will help convince more countries. Diversified supply of vaccines, with viable alternatives from China, is key to ensuring fair and equitable access by poor countries,” said the op-ed.

SinoPharm revealed that senior officials in Egypt and Bahrain also took part in trials held there.

https://asiatimes.com/2020/12/uae-gives-chinese-vaccines-a-shot-in-the-arm/
10/12/2020 11:55 PM
NPRA1985 FDA intends to 'proceed towards an authorization' of Covid-19 vaccine, official says, as cases soar

(CNN)The FDA has informed Pfizer it intends "to proceed towards an authorization" of the manufacturer's Covid-19 vaccine, the US Health and Human Services Secretary told ABC on Friday morning, as the country is deep into a worsening health crisis.

The statement comes a day after an FDA panel recommended the agency grant an emergency use authorization for the Pfizer-BioNTech coronavirus vaccine.Other key steps remain, but if those hurdles are cleared, the first vaccinations in the US could happen early next week, HHS Secretary Alex Azar told ABC's George Stephanopoulos.

"The FDA informed Pfizer that they do intend to proceed toward an authorization for their vaccine," Azar told ABC Friday morning.

https://edition.cnn.com/2020/12/11/health/us-coronavirus-friday/index.html
12/12/2020 2:26 AM
NPRA1985 Pfizer Vaccine Cleared in U.S., a Landmark in Covid-19 Fight

Pfizer Inc. gained emergency U.S. authorization for its Covid-19 vaccine on Friday, completing an unprecedented scientific sprint that could eventually help bring an end to a pandemic that has killed nearly 300,000 Americans

https://www.bloomberg.com/news/articles/2020-12-12/pfizer-covid-vaccine-wins-u-s-fda-emergency-use-authorization
12/12/2020 3:04 PM
NPRA1985 Bursa Malaysia is expected to trend higher next week

https://www.malaymail.com/news/money/2020/12/12/bursa-malaysia-is-expected-to-trend-higher-next-week/1931258

----------------

Bursa Malaysia expected to break 1,700 psychological level

Bursa Malaysia is expected to trend higher next week, with the key FTSE Bursa Malaysia KLCI (FBM KLCI) breaking the psychological level of 1,700, and poised to march into the new year with a big bang.

https://themalaysianreserve.com/2020/12/12/bursa-malaysia-expected-to-break-1700-psychological-level/
12/12/2020 6:05 PM
FT1981 this counter not active?
07/01/2021 11:19 AM
FT1981 https://app.sinchew.com.my/content/content_2406317.html?type=detail&fileId=2406317&colID=6660
07/01/2021 11:20 AM
NPRA1985 Post removed. Why?
03/02/2021 10:03 PM
KaiHong this is a stable stock
15/02/2021 3:00 PM
Aa01182 Sleeping giant
11/03/2021 11:02 PM
jomvalueinvest2 Vaccine counter wave coming ? Kanger seems like more hot now
18/05/2021 2:39 PM
Mr.Sm Invest123 Apex Healthcare Bhd
Target price: RM3.33 BUY


AMINVESTMENT BANK RESEARCH (MAY 24): The drag from associated company Straits Apex Sdn Bhd (SA) is expected to ease in the coming quarters. Major customer Smith and Nephew Sales Sdn Bhd, which contributes to about 62% of SA sales, performed the bulk of 1QFY21’s transactions in 4QFY20. Pandemic uncertainty has also led it to delay the bulk of its remaining orders to 2HFY21. Currently, order levels are similar to last year’s.

However, poor utilisation rates at SPP NOVO are expected to keep manufacturing segment margins depressed; therefore, the group is deferring expansion plans until pharmaceutical demand returns.

Meanwhile, rising freight and raw material costs are likely to compress margins in the coming quarters. While ASPs for group brand products remain unchanged, they may rise in the coming quarters. External products have already seen a 6% increase in ASP.

With the Ministry of Health’s (MoH) expenses tied up by the pandemic’s resurgence, the group believes government tenders are hard to come by at the moment. We expect this to normalise in FY22F, as the bulk of the MoH’s mass vaccinations will have already been completed by then. Going forward, we remain positive on Apex’s future prospects as a recovery play.
07/06/2021 6:49 PM
wallstreetrookie A Guide to Investing in Healthcare Companies

Low tier: IHH, TopGlove, Supermaxm Pharmaniaga
High tier: YSPSAH, Apex Healthcare, Duopharma
10/06/2021 3:03 PM
wallstreetrookie Though the company only gets a small slice of the meat within the pharmaceutical business, manufacturing generic medication remains profitable and attractive for defensive investments.
22/06/2021 4:55 AM
wallstreetrookie I like this company
24/06/2021 6:20 AM
wallstreetrookie Political instability always presents the best opportunities to buy the dips. When everyone's attention is grabbed by glove companies, it is the perfect chance to buy in alternative healthcare and pharmaceutical companies. And for what's worth, Apex Healthcare is a well-managed company
24/06/2021 1:02 PM
wallstreetrookie If you want defensive stocks, this is the one
24/06/2021 11:32 PM
CynicalCyan 21 years ago, AHEALTH was first listed on the Second Board with around 100 mil in market capitalisation.
21 years later, AHEALTH became one of the most consistent profitable companies on Bursa Main Market with about 1 bil in market capitalisation.

Hats off to such an outstanding Malaysian company. May the next 21 years be even better.
26/06/2021 10:29 PM
telurgoreng Apex and YSP are both good defensive counters. But YSP seems to be the better value given the price and dividend yield.
15/07/2021 4:19 PM
Hafid PROBLEM IS NO GROWTH
15/07/2021 4:21 PM
telurgoreng They are investing a lot into production, machine and factories hence less money to be given out as dividends. The share is non-speculative due to most of the holdings are held by the directors and owners. Hence it is very hard to goreng shares like this. These are the "Tanker" shares, they can easily tank recession and outlast the smallcap counters.

If you prefer gambling and speculative shares, you're better off buying penny stocks as those have almost 0 returns and price swing wildly due to rumours and speculation. Depending on which type of investor you are, some people prefer insurance and banking, some people prefer healthcare, some prefer energy, some people just follow the wind and hype according to what come out in the newspaper during the moment.. Price movement may be boring, but this is for slow and steady, keep for long term or retirement kind like bank shares.

My take is, the share hasn't seen any bonus in over 10 years. They have grown steadily in terms of asset. Hence, I foresee they may issue bonus eventually when the industry recovers and we are in better financial situation. It's not like they're having debt problems or not-profitable. The share price is just boring cause most of the shareholding held by the owners and directors, so there is not enough public shares for operators to goreng.
15/07/2021 10:47 PM
Nepo Apex declared bonus issues in Year 2018
16/07/2021 6:08 AM
Hafid I rather wait until below rm1.40
17/07/2021 5:21 AM
Bgt 9963 Good morning.
17/07/2021 9:04 AM